Source - SMW
Midatech Pharma said it had received approval from the US Food and Drug Administration to conduct a study of MTX110, an investigational nano-inclusion product, for the treatment of the fatal childhood brain cancer DIPG.

The disease occurs mainly in young children and has a median survival of nine months. 

With no treatment currently approved, the approval of the trial could be a big step towards developing a treatment for this cancer, the company said.


At 9:59am: (LON:MTPH) Midatech Pharma Plc share price was +1p at 45.5p